Cinclus Pharma Holding AB (publ) (STO:CINPHA)
Sweden · Delayed Price · Currency is SEK 17.48
+0.04 (0.23%)
At close: Mar 2, 2026
Cinclus Pharma Holding AB Revenue
In the year 2025, Cinclus Pharma Holding AB had annual revenue of 57.47M SEK with 1,154.80% growth. Cinclus Pharma Holding AB had revenue of 13.63M in the quarter ending December 31, 2025, with 197.64% growth.
Revenue
57.47M
Revenue Growth
+1,154.80%
P/S Ratio
14.15
Revenue / Employee
2.74M
Employees
21
Market Cap
813.48M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 57.47M | 52.89M | 1,154.80% |
| Dec 31, 2024 | 4.58M | -1.38M | -23.14% |
| Dec 31, 2023 | 5.96M | -4.61M | -43.63% |
| Dec 31, 2022 | 10.57M | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| BioGaia AB | 1.54B |
| EQL Pharma AB | 425.75M |
| Nanexa AB | 55.94M |
| Enzymatica AB | 53.90M |
| Cereno Scientific AB | 44.27M |
| Orexo AB | 26.00M |
| Moberg Pharma AB | 13.54M |
| Klaria Pharma Holding AB (publ.) | 8.99M |